Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.41 |
| ▸ | TUBB | P07437 | 3/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140089 | 0.76 | ALDH1A1 (0.36) | CYP3A4MAPTACHECA9ALDH1A1 | |
| SCHEMBL4184604 | 0.74 | TUBB1 (0.36) | CYP3A4MAPTACHETUBB1 | |
| SCHEMBL1021384 | 0.74 | CA2 (0.48) | CYP3A4ACHECA9PTGS2TUBB1 | |
| SCHEMBL429756 | 0.72 | ACHE (0.59) | CYP3A4MAPTACHECA9PTGS2 | |
| Antiarol SCHEMBL210578 | 0.72 | CYP3A4 (1.00) | CYP3A4MAPTACHECA9PTGS2 | |
| SCHEMBL28996996 | 0.71 | ACHE (0.35) | CYP3A4MAPTACHECA9TUBB1 | |
| SCHEMBL721861 | 0.71 | ACHE (0.65) | CYP3A4MAPTACHECA9PTGS2 | |
| SCHEMBL6947358 | 0.70 | ACHE (0.56) | CYP3A4MAPTACHECA9PTGS2 | |
| SCHEMBL3000499 | 0.70 | ALDH1A1 (0.58) | CYP3A4CA9PTGS2TUBB1TUBB4A | |
| SCHEMBL1337032 | 0.70 | ACHE (0.56) | CYP3A4MAPTACHECA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| CN-106380790-A | Liquid crystal polyester molding composition and application thereof | 金发科技股份有限公司 | 2017-02-08 | — | — | CN | claimed |
| EP-1121338-A4 | METHOD FOR SYNTHESIZING DIARYL-SUBSTITUTED HETEROCYCLIC COMPOUNDS, INCLUDING TETRAHYDROFURANS | MILLENNIUM PHARM INC (US) | 2003-03-12 | — | — | EP | claimed |
| US-20020128491-A1 | Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans | RAO ALLA VENKATA RAMA (IN) | 2002-09-12 | — | — | US | claimed |
| EP-1121338-A1 | METHOD FOR SYNTHESIZING DIARYL-SUBSTITUTED HETEROCYCLIC COMPOUNDS, INCLUDING TETRAHYDROFURANS | Millennium Pharmaceuticals, Inc. (US) | 2001-08-08 | — | — | EP | claimed |
| WO-2000023409-A1 | METHOD FOR SYNTHESIZING DIARYL-SUBSTITUTED HETEROCYCLIC COMPOUNDS, INCLUDING TETRAHYDROFURANS | LEUKOSITE, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| US-20260007640-A1 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-5292946-A | Reducing agent | MERCK & CO., INC. (US) | 1994-03-08 | — | — | US | disclosed |
| EP-0574510-A1 | NEOLIGNAN DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS AND 5-LIPOXYGENASE INHIBITORS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-12-22 | — | — | EP | disclosed |
| WO-1992015294-A1 | NEOLIGNAN DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS AND 5-LIPOXYGENASE INHIBITORS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-09-17 | — | — | WO | disclosed |
| EP-0478062-A1 | In-situ preparation of diisopinocampheyl chloroborane | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| EP-0478063-A1 | Method of making optically active alcohols | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| US-5099033-A | Condensation of bromine compound with organometallic compound to form platelet activating factor antagonist, anticoagulants, hypotensives, antiinflammatory agents and cardiovascular disorders | MERCK & CO., INC. (US) | 1992-03-24 | — | — | US | disclosed |
| EP-0465122-A1 | Process of making 2,5-diaryl tetrahydrofurans and analogs thereof useful as paf antagonists | MERCK & CO. INC. (US) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | CYP3A4 4225/4885MAPT 2614/4885ACHE 3555/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | CYP3A4 256/4885MAPT 4544/4885ACHE 4515/4885 |
| US-20260007640-A1 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MYD88, TLR9, TLR5 | CYP3A4 1665/4885MAPT 3863/4885ACHE 2096/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CYP3A4 4225/4885MAPT 2614/4885ACHE 3555/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CYP3A4 4225/4885MAPT 2614/4885ACHE 3555/4885 |
| US-20020128491-A1 | Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans | TPMT, TPI1, GTF2I | CYP3A4 291/4885MAPT 1577/4885ACHE 2623/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | CYP3A4 4225/4885MAPT 2614/4885ACHE 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.